192 related articles for article (PubMed ID: 23291300)
1. Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical Products.
Sargent EV; Faria E; Pfister T; Sussman RG
Regul Toxicol Pharmacol; 2013 Mar; 65(2):242-50. PubMed ID: 23291300
[TBL] [Abstract][Full Text] [Related]
2. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
3. Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs).
Bercu JP; Morinello EJ; Sehner C; Shipp BK; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S48-56. PubMed ID: 27233925
[TBL] [Abstract][Full Text] [Related]
4. Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance.
Bercu JP; Sharnez R; Dolan DG
Regul Toxicol Pharmacol; 2013 Feb; 65(1):157-61. PubMed ID: 22921793
[TBL] [Abstract][Full Text] [Related]
5. Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials.
Bercu JP; Dolan DG
Regul Toxicol Pharmacol; 2013 Feb; 65(1):162-7. PubMed ID: 22732128
[TBL] [Abstract][Full Text] [Related]
6. Using default methodologies to derive an acceptable daily exposure (ADE).
Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
[TBL] [Abstract][Full Text] [Related]
7. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
[TBL] [Abstract][Full Text] [Related]
8. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
9. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
10. Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.
Olson MJ; Faria EC; Hayes EP; Jolly RA; Barle EL; Molnar LR; Naumann BD; Pecquet AM; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S19-27. PubMed ID: 27233923
[TBL] [Abstract][Full Text] [Related]
11. Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach.
Maier MS
Toxicol Mech Methods; 2011 Feb; 21(2):76-85. PubMed ID: 20156007
[TBL] [Abstract][Full Text] [Related]
12. Strategies for preventing occupational exposure to potent compounds.
Calhoun DM; Coler AB; Nieusma JL
Toxicol Mech Methods; 2011 Feb; 21(2):93-6. PubMed ID: 20507226
[TBL] [Abstract][Full Text] [Related]
13. Setting occupational exposure limits for pharmaceuticals.
Naumann BD; Sargent EV
Occup Med; 1997; 12(1):67-80. PubMed ID: 9153053
[TBL] [Abstract][Full Text] [Related]
14. Identifying and assessing highly hazardous drugs within quality risk management programs.
Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
[TBL] [Abstract][Full Text] [Related]
15. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
Tanyous JN
PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
[TBL] [Abstract][Full Text] [Related]
16. Background, approaches and recent trends for setting health-based occupational exposure limits: a minireview.
Nielsen GD; Ovrebø S
Regul Toxicol Pharmacol; 2008 Aug; 51(3):253-69. PubMed ID: 18502550
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
18. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
19. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
20. Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approach.
Sehner C; Bernier T; Blum K; Clemann N; Glogovac M; Hawkins WA; Kohan M; Linker F; Lovsin-Barle E; Osadolor O; Pfister T; Schulze E; Schwind M; Tuschl G; Wiesner L
Regul Toxicol Pharmacol; 2024 Jun; 150():105649. PubMed ID: 38782234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]